Biogen Inc. (NASDAQ: BIIB) reported its financial results for the quarter ended March 31, 2020 today.
Biogen posted a 1% decline in earnings for the first quarter of 2020 due to higher costs and expenses despite a 1% rise in the top-line. The company continued to develop and expand its pipeline, including making good progress toward the US regulatory filing for aducanumab, as well as bolstering its efforts in gene therapy through a collaboration with Sangamo.
The company believes that the magnitude and uncertainty surrounding the COVID-19 pandemic clearly introduce unanticipated and potentially unquantifiable risks to its business and results over the near-term. While Biogen does expect there will be some impact on timelines for certain of its clinical programs, it still expects the vast majority of the 10 remaining near-term readouts to occur before the end of 2021.
Past Performance
Most Popular
FDX Earnings: FedEx Q1 adjusted earnings drop; revenue up 5%
Cargo giant FedEx Corporation (NYSE: FDX) Thursday reported a decline in first-quarter adjusted earnings, despite an increase in revenues. The company also provided guidance for fiscal 2023. Net income, adjusted
Key highlights from Darden Restaurants (DRI) Q1 2023 earnings results
Darden Restaurants, Inc. (NYSE:DRI) reported first quarter 2023 earnings results. Total sales increased 6.1% year-over-year to $2.4 billion, driven by blended same-restaurant sales growth of 4.2%. Net earnings amounted to
ACN Earnings: Key quarterly highlights from Accenture’s Q4 2022 financial results
Accenture (NYSE: ACN) reported fourth quarter 2022 earnings results today. Total revenues were $15.4 billion, up 15% year-over-year in US dollars and up 22.4% in local currency. Net income attributable
